STX Shield Therapeutics

Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team

Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team

15-Nov-2023 / 07:30 GMT/BST
The issuer is solely responsible for the content of this announcement.

Hardman & Co Research on Shield Therapeutics (STX):

Accelerating effectiveness of enlarged sales team

 

Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating characteristics of Accrufer® as an oral ID drug, with the aim of ramping up prescription (Rx) growth and sales traction. Positive Rx momentum in 2022 started to accelerate at the end of 1Q’23 and has continued into 3Q’23, following expansion of the Shield-Viatris commercial team. In the event that the US goals are achieved, there would be considerable upside potential to the valuation.

Please click on the link below for the full report:

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co

Follow us on Twitter @HardmanandCo

Contact:

Martin Hall

 

 



 

Hardman & Co Research can still be accessed for free after MiFID II. Please to read the statement.

About Hardman & Co: Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259. Attention is drawn to the important disclaimers at the end of the report.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service

1773471  15-Nov-2023 

fncls.ssp?fn=show_t_gif&application_id=1773471&application_name=news&site_id=research_pool
EN
15/11/2023

Underlying

STXShield Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Shield Therapeutics

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
STX Shield Therapeu...
W7L WARPAINT LONDON ... (+10)

Hybridan Small Cap Feast: 9 February 2026

* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Versarien (VRS.L) left AIM. What’s baking in the oven? Market Movers:*** 14 January: GlobalData (DATA.L), the data, insight, a...

STX SHIELD THERAPEUTICS
W7L WARPAINT LONDON
PXC PHOENIX COPPER
POW POWER METAL RESOURCES
AREC ARECOR THERAPEUTICS
DEVO DEVOLVER DIGITAL INC
AURR AURRIGO INTERNATIONAL PLC
PALM PANTHER METALS PLC
PWR POWER PROBE PLC
NEWS PATHOS COMMUNICATIONS LIMITED
02/09/26 February 9, 2026 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
GTC GETECH GROUP
STX Shield Therapeu... ... (+8)

Hybridan Monthly - February Edition

Hybridan Monthly, 3 February 2026 Market Comment: By Niall Pearson For a special February 2026 edition of Hybridan’s View from the Broker’s Desk, we are delighted to be joined by Laurence Hulse, founder of Onward Opportunities, a leading UK Small Cap Investment Trust. Laurence started his career at Gresham House in 2015, around the time of its inception, and worked on a number of outperforming equity products. Recently, Onward Opportunities reported a record year of net asset value growth in the...

GTC GETECH GROUP
STX SHIELD THERAPEUTICS
CGNR CONROY GOLD & NATURAL RESOURCES
N4P N4 PHARMA
1SN FIRST TIN PLC
OBI ONDINE BIOMEDICAL INC.
RCFX RC FORNAX PLC
QUBE QUANTUM BASE HOLDINGS
02/04/26 February 4, 2026 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
AAU Ariana Resource...
IKA ILIKA ... (+10)

Hybridan Small Cap Feast: 21 January 2026

21st January 2026 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: None What’s baking in the oven? IPOs:** 14th January...

AAU ARIANA RESOURCES
IKA ILIKA
OPTI OPTIBIOTIX HEALTH
STX SHIELD THERAPEUTICS
KEFI KEFI GOLD AND COPPER
GETB GETBUSY
JNEO JOURNEO PLC
LETS LET'S EXPLORE GROUP PLC
TAND TAN DELTA SYSTEMS
FRG FIRERING STRATEGIC MINERALS PLC
01/21/26 January 21, 2026 1 EN
Martin Hall
  • Martin Hall
TRX Tissue Regenix ...
AGY Allergy Therape... ... (+11)

Hardman & Co Healthcare Index: 2025 – Index rose, but another tough ye...

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. After three years of annual declines, the HHI rebounded 17.6% to 469.1 in 2025. While this sounds positive, it was below the strong performance of most major UK healthcare stocks and, in general, it underperformed its UK and peer benchmarks: FTSE 100 (+21.5%); FTSE All-Share (+19.8%); and the NASDAQ Biotech Index (NBI; +32.4%). Th...

TRX TISSUE REGENIX GROUP
AGY ALLERGY THERAPEUTICS PLC
FUM FUTURA MEDICAL PLC
IMM IMMUPHARMA
HVO HVIVO
INDV INDIVIOR PLC
VAL VALIRX
STX SHIELD THERAPEUTICS
GDR GENEDRIVE
GSK GLAXOSMITHKLINE PLC
FAB FUSION ANTIBODIES
01/14/26 January 14, 2026 1 EN
Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson
AAU Ariana Resource...
STX Shield Therapeu... ... (+9)

Hybridan Small Cap Feast: 3 December 2025

3rd December 2025 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: Yes...

AAU ARIANA RESOURCES
STX SHIELD THERAPEUTICS
ALBA ALBA MINERAL RESOURCES PLC
PIRI PIRES INVESTMENTS
PYC PHYSIOMICS PLC
SYS SYSGROUP
GENI GENINCODE PLC
ONDO ONDO INSURTECH PLC
HERC HERCULES SITE SERVICES PLC
12/03/25 December 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch